| Code | CSB-RA733578MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to Enoblituzumab, designed to specifically target CD276 (B7-H3), a member of the B7 family of immune checkpoint proteins. CD276 is a transmembrane glycoprotein that functions as an immune regulatory molecule, modulating T-cell activation and proliferation. Under normal physiological conditions, CD276 exhibits limited expression in healthy tissues, but becomes significantly overexpressed across numerous solid tumors, including bladder, prostate, lung, breast, and ovarian cancers. This aberrant expression correlates with tumor progression, metastasis, and poor clinical prognosis, making CD276 an attractive target for cancer immunotherapy research.
Enoblituzumab, the reference antibody, is a humanized IgG1 monoclonal antibody that has been investigated in clinical trials for various malignancies, particularly head and neck squamous cell carcinoma and bladder cancer. This biosimilar provides researchers with a valuable tool for investigating CD276-mediated immune evasion mechanisms, tumor microenvironment interactions, and potential therapeutic strategies targeting this checkpoint molecule. The antibody supports diverse oncology research applications exploring novel immunotherapeutic approaches.
There are currently no reviews for this product.
Earlier studies found that B7H3 (also known as B7H3) promotes the activation of T cells. Chapoval et al. confirmed that in the presence of anti-CD3 antibodies, B7H3 can promote the proliferation of CD4 and CD8+ T cells and selectively promote the secretion of IFN-γ. And B7H3 transfection into tumor cells can enhance the killing ability of CTL. Further research found that only TLT-2 transgenic cells could bind to mouse B7H3 with high affinity, and TLT-2 was determined to be the receptor molecule of B7H3. Moreover, Hashiguchi et al. confirmed that the B7H3-TLT-2 pathway enhanced T cell activation. However, Leitner et al. did not find the specific binding of B7H3 to TLT-2 by flow cytometry, therefore, the exact receptor molecule of B7H3 is still unclear.
On the other hand, studies have found that B7H3 can also suppress T-cell immune responses. Some studies have shown that B7H3 can inhibit human and mouse T cells by activating or inhibiting NFTA (nuclear factor for activated T cells), NF-KB (nuclear factor kB) and AP-1 (activator protein-1) pathways. activation. In addition, results have demonstrated that B7H3 may inhibit T cell immune responses by inhibiting the activity of Thl. The study of Leiner et al. also found that B7H3 can down-regulate the secretion of IL-2 in T cells to inhibit the activity of T cells.